<DOC>
	<DOCNO>NCT01792102</DOCNO>
	<brief_summary>This Phase 1/2 , multicenter , open label , dose-escalation , nonrandomized study evaluate safety , pharmacodynamics , efficacy 60-minute infusion carfilzomib patient progressive multiple myeloma .</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacodynamics 60-Minute Infusion Carfilzomib Progressive Multiple Myeloma</brief_title>
	<detailed_description>This Phase 1/2 , multicenter , open label , dose-escalation , nonrandomized study evaluate safety , pharmacodynamics , efficacy 60-minute infusion carfilzomib patient progressive multiple myeloma . The study consist screening period , follow treatment period eight 28-day treatment cycle , follow period maintenance treatment . Subjects treat disease progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . MM relapse progressive disease study entry . Defined progressive MM patient 's last treatment regimen 2 . Measurable disease , define one following ( assess within 14 day prior first dose ) : 1 . Serum Mprotein ≥ 0.5 g/dL , 2 . Urine Mprotein ≥ 200 mg/24 hour , 3 . Only patient meet b , use serum free light chain ( SFLC ) &gt; 100 mg/L ( involved light chain ) abnormal kappa/lamda ratio 3 . Age ≥ 18 year 4 . Life expectancy ≥ 6 month 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 6 . Adequate hepatic function within 14 day prior first dose , bilirubin &lt; 1.5 × upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 × ULN 7 . LVEF ≥ 40 % . 2D transthoracic echocardiogram ( ECHO ) prefer method evaluation . Multigated Acquisition Scan ( MUGA ) acceptable ECHO available . 8 . Absolute neutrophil count ( ANC ) ≥ 1000/mm3 within 14 day prior first dose . Screening ANC independent granulocyte colony stimulate factor support ≥ 1 week pegylated granulocyte colony stimulate factor ≥ 2 week . 9 . Hemoglobin ≥ 8.0 g/dL within 14 day prior enrollment . Use erythropoietic stimulating factor red blood cell ( RBC ) transfusion per institutional guideline allow . 10 . Platelet count ≥ 75,000/mm3 ( ≥ 50,000/mm^3 myeloma involvement bone marrow &gt; 50 % ) within 14 day prior first dose . Patients must receive platelet transfusion least 7 day prior obtain screen platelet count 11 . Calculated measured creatinine clearance ( CrCl ) ≥ 15 mL/min within 14 day prior first dose . Calculation base standard formula , Cockcroft Gault : [ ( 140 Age ) x Mass ( kg ) / ( 72 x Creatinine mg/dL ) ] ; multiply result 0.85 female 12 . Written inform consent accordance federal , local , institutional guideline 13 . Female patient childbearing potential ( FCBP ) must negative serum pregnancy test within 14 day prior first dose agree use effective method contraception 3 month follow last dose drug ( frequent pregnancy test may conduct require per local regulation ) . Postmenopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt pregnancy test 14 . Male patient must agree use effective barrier method contraception study 3 month follow last dose sexually active FCBP 1 . Multiple myeloma IgM subtype 2 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 3 . Plasma cell leukemia ( &gt; 2.0 × 109/L circulate plasma cell standard differential ) 4 . Waldenström 's macroglobulinemia 5 . Amyloidosis 6 . Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent ) within 7 day prior first dose 7 . Cytotoxic chemotherapy approve investigational anticancer therapeutic within 28 day prior first dose 8 . Treatment bortezomib , thalidomide lenalidomide within 21 day prior first dose 9 . Focal radiation therapy within 7 day prior first dose . Radiation therapy extend field involve significant volume bone marrow within 21 day prior enrollment ( i.e. , prior radiation must &lt; 30 % bone marrow ) 10 . Immunotherapy within 21 day prior first dose 11 . Major surgery within 21 day prior first dose 12 . Active congestive heart failure ( New York Heart Association [ NYHA ] Classes III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within 6 month prior first dose . 13 . Acute active infection require systemic antibiotic , antiviral ( except antiviral therapy direct HBV ) , antifungal agent within 14 day prior first dose 14 . Known human immunodeficiency virus ( HIV ) seropositivity 15 . Known hepatitis B C virus infection ( except patient HBV receive respond HBV antiviral therapy : patient allow ) 16 . Patients know cirrhosis 17 . Second malignancy within past 3 year , except : 1 . Adequately treat basal cell squamous cell skin cancer 2 . Carcinoma situ cervix 3 . Prostate cancer &lt; Gleason score 6 stable prostatespecific antigen ( PSA ) 12 month 4 . Breast carcinoma situ full surgical resection 5 . Treated medullary papillary thyroid cancer 6 . Patients myelodysplastic syndrome 18 . Significant neuropathy ( Grades 3 4 ) within 14 day prior first dose 19 . Peripheral neuropathy pain ≥ G2 within 14 day prior first dose 20 . Female patient pregnant lactate 21 . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) 22 . Prior carfilzomib treatment 23 . Prior participation Onyxsponsored phase 3 trial 24 . Patients contraindication dexamethasone 25 . Contraindication require concomitant drug supportive treatment , include hypersensitivity antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment 26 . Ongoing graftversushost disease 27 . Patients pleural effusion require thoracentesis ascites require paracentesis within 14 day prior enrollment 28 . Uncontrolled hypertension uncontrolled diabetes within 14 day prior enrollment 29 . Any clinically significant medical disease psychiatric condition , Investigator 's opinion , may interfere protocol adherence patient 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Krypolis</keyword>
	<keyword>60 minute infusion</keyword>
</DOC>